Investors that missed out on the IPO for medtech company 4D Medical (ASX: 4DX) have had no qualms buying the stock on market with shares in 4DX opening at $1.47 when trading commenced this morning, more than double the IPO Offer Price of $0.73. The significant jump follows a similar trend among Australian investors that
Read More
With Queensland’s swift management of COVID-19, the Sunshine State is set to recover quicker than its southern neighbours and the State Government is aiming to restart its tourism industry via a $69.9m support package for Ardent Leisure (ASX: ALG) which will re-open Dreamworld and WhiteWater World in September. The financial assistance packages totaling $69.9 million
Read More
Financial difficulties created by Stage 4 lockdowns have tightened the budgets of most Victorian families but thankfully, the State’s economy is well stocked up on thoughts and prayers. There has been an outpouring of “thoughts and prayers” from Australian politicians being sent to the State but as the Victorian economy notes, it’s very difficult to
Read More
Environmental intelligence company Envirosuite (ASX: EVS) is looking to extend the world’s sustainable consumption capabilities having acquired technology that can optimise wastewater treatment plants using artificial intelligence and machine learning. The water modelling technology has been purchased for $1.35m from Aqueous Material Balance (AqMB) and enables users to run hypothetical changes to chemical and biological
Read More
With online retail thriving through the pandemic, eCommerce company Crowd Media (ASX: CM8) is set to build on their strong FY20 performance having entered into a partnership with US-based Teadora Inc to market natural Brazilian beauty products through Europe, including the Amazon EU marketplace. Leveraging their extensive network of more than 1,000 social influencers, Crowd
Read More
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life sciences stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is
Read More